- Home
- LRE vs QNCX Comparison
LRE vs QNCX Comparison
Compare LRE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | QNCX |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 19.9M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LRE | QNCX |
|---|---|---|
| Price | $1.28 | $1.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.7K | ★ 1.4M |
| Earning Date | 07-30-2015 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ $0.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.08 |
| 52 Week High | $2.86 | $4.55 |
Technical Indicators
Market Signals| Indicator | LRE | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 46.14 |
| Support Level | $1.19 | $0.79 |
| Resistance Level | $1.40 | $1.45 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 50.66 | 44.64 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.